bioRxiv Science⌕ Search

bioRxiv · 10.1101/2020.03.23.003269

A disordered encounter complex is central to the yeast Abp1p SH3 domain binding pathway

Abstract

Protein-protein interactions are involved in a wide range of cellular processes. These interactions often involve intrinsically disordered proteins (IDPs) and protein binding domains. However, the details of IDP binding pathways are hard to characterize using experimental approaches, which can rarely capture intermediate states present at low populations. SH3 domains are common protein interaction domains that typically bind proline-rich disordered segments and are involved in cell signaling, regulation, and assembly. We hypothesized, given the flexibility of SH3 binding peptides, that their binding pathways include multiple steps important for function. Molecular dynamics simulations were used to characterize the steps of binding between the yeast Abp1p SH3 domain (AbpSH3) and a proline-rich IDP, ArkA. Before binding, the N-terminal segment 1 of ArkA is pre-structured and adopts a polyproline II helix, while segment 2 of ArkA (C-terminal) adopts a 310 helix, but is far less structured than segment 1. As segment 2 interacts with AbpSH3, it becomes more structured, but retains flexibility even in the fully engaged state. Binding simulations reveal that ArkA enters a flexible encounter complex before forming the fully engaged bound complex. In the encounter complex, transient nonspecific hydrophobic and long-range electrostatic contacts form between ArkA and the binding surface of SH3. The encounter complex ensemble includes conformations with segment 1 in both the forward and reverse orientation, suggesting that segment 2 may play a role in stabilizing the correct binding orientation. While the encounter complex forms quickly, the slow step of binding is the transition from the disordered encounter ensemble to the fully engaged state. In this transition, ArkA makes specific contacts with AbpSH3 and buries more hydrophobic surface. Simulating the binding between ApbSH3 and ArkA provides insight into the role of encounter complex intermediates and nonnative hydrophobic interactions for other SH3 domains and IDPs in general. Author SummaryComplex cellular processes are mediated by interactions between proteins, and to determine how these interactions affect cellular function and binding kinetics we often must understand the protein binding pathway. Many protein interaction domains, such as the SH3 domain, bind to intrinsically disordered proteins in a coupled folding and binding process. Using molecular dynamics simulations, we find that the binding of the disordered ArkA peptide to the yeast Abp1p SH3 domain proceeds through a flexible, disordered encounter complex before reaching a stable fully bound state. The encounter complex is stabilized by nonspecific long-range electrostatic interactions and nonspecific hydrophobic interactions between the peptide and domain. Our simulations highlight the important role of hydrophobic interactions in the entire SH3 binding process: both nonspecific hydrophobic contacts in the encounter complex and specific hydrophobic contacts in the fully bound complex. The encounter complex could be key to understanding the functional behavior of SH3 domain interactions because the encounter complex forms very quickly and the transition to the fully bound state is slower. In cells, an SH3 domain may form an encounter complex quickly and nonspecifically with many potential binding partners, allowing it to search for the correct recognition sequence before completing the binding process.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gerlach, G. J., Carrock, R., Stix, R., Stollar, E. J., Ball, K. A.. 2020-03-23. A disordered encounter complex is central to the yeast Abp1p SH3 domain binding pathway. https://doi.org/10.1101/2020.03.23.003269

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A Deformulating Multi-Attribute SEC Method for Simultaneous Quantification of Total RNA, Conjugated Antibody, and Free Antibody in Targeted Lipid Nanoparticles

Targeted lipid nanoparticles (tLNPs) hold promise for improving cell- and tissue-selective delivery of therapeutic payloads but introduce analytical challenges associated with characterizing both encapsulated cargo and surface-associated targeting ligands within the same formulation. Conventional nucleic acid and protein assays can be affected by nanoparticle scattering, matrix interference, or a limited ability to distinguish conjugated antibody from free antibody. Here, we report an online deformulating size-exclusion high-performance liquid chromatography (SE-HPLC) method that enables simultaneous quantification of total RNA, conjugated antibody, and free antibody from 5 L of tLNP sample. Following injection, exposure to a mobile phase containing sodium dodecyl sulfate and isopropanol disrupts the nanoparticles, enabling chromatographic separation of RNA, conjugated antibody, and free (unconjugated) antibody while minimizing sample handling prior to analysis. RNA was quantified by UV260 detection, whereas antibody was quantified by UV280 or intrinsic fluorescence detection to maximize sensitivity. The method demonstrated linear response over the evaluated concentration ranges, spike recoveries of 88-122%, and precision below 5% relative standard deviation. Application to purified tLNP formulations demonstrated simultaneous assessment of total RNA and conjugated antibody content, while confirming the absence of detectable free antibody following purification. Together, these results establish online deformulating SE-HPLC as a practical multi-attribute analytical method for characterization of tLNPs, enabling concurrent assessment of total RNA concentration, conjugated antibody concentration, and free antibody concentration using standard HPLC instrumentation.

biophysics↗

Nanomechanical phenotyping uncovers a non-canonical smooth muscle-like hypercontractility program in lung squamous cell carcinoma myofibroblasts

Myofibroblast-like cancer-associated fibroblasts (myCAFs) drive the stiff, tumor-promoting microenvironment, yet their mechanical phenotype in non-small cell lung cancer (NSCLC) remains undefined. myCAFs from major NSCLC subtypes (lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC)) were examined combining atomic force microscopy and traction force microscopy with molecular and signaling analyses. LUAD-myCAFs displayed canonical myofibroblast features, including elevated stiffness, traction forces, ROCK-MYPT1 signaling, and -SMA-rich stress fibers. Unexpectedly, LUSC-myCAFs amplified these nanomechanical features despite reduced ROCK-MYPT1 signaling and comparable -SMA levels. Instead, they exhibited a smooth muscle cell (SMC)-like contractile program characterized by enhanced SM-MHC(MYH11) expression colocalized with -SMA, ERK1/2-RLC hyperactivation, and DNA methylation reprogramming including SMC-contractility regulators. LUSC-myCAF hypercontractility was linked with reduced proliferative capacity and smaller intratumoral vessel lumens, consistent with the low CAF density and enhanced hypoxia patterns reported in LUSC. SMC markers were enriched and associated with adverse outcomes selectively in LUSC, highlighting the relevance of SMC-like myCAFs in LUSC progression. These findings unveil subtype-specific myCAF programs in NSCLC, and identify -SMA/SM-MHC(MYH11) myCAFs as key determinants of tumor mechanics, providing a rationale for the survival benefits of antihypertensive drugs targeting SMC hypercontractility. Moreover, they demonstrate that nanomechanical phenotyping can uncover translationally relevant myCAF phenotypes invisible to molecular profiling.

biophysics↗

Engineering Nanobody Conformational Switches

Conformational signaling is widely used in biology, but remains difficult to engineer into proteins. Here, we explore ligand-induced folding of nanobodies as a general strategy to generate conformational receptors for a broad range of target ligands. More specifically, we have generated partially unfolded nanobody variants that fold exclusively upon binding to their target ligand. To do so, we have introduced destabilizing mutations in the framework region, carefully tuning their stability while preserving molecular recognition. Given the high conservation of the framework across different nanobodies, this approach is broadly applicable to many other target ligands, which has enabled us to engineer conformational switches for three different important biomarkers and drugs: the pregnancy hormone chorionic gonadotropin, the cytokine tumor necrosis factor alpha, and the chemotherapy and immunosuppressant drug methotrexate. Another useful property of conformational signaling is that it can directly gate signal transduction, which we have leveraged to build an optical sensor for the quantitative detection of the pregnancy hormone in urine. Finally, conformational signaling introduces new mechanisms for the allosteric modulation of binding, which we have explored to control the affinity and dynamic range of the sensor. Our work thus establishes a rational strategy for engineering conformational signaling receptors with customizable properties and generalizable for many different target ligands.

biophysics↗